Patient Death Reported in French Painkiller Trial
Private laboratory Biotrial was testing a pain and mood disorder medication for Portuguese pharma company Bial on humans for the first time, in a Phase I trial.
Details are starting to emerge in the European media about a clinical trial in Rennes, north-west France, that went seriously wrong and reportedly has killed one volunteer and led to five hospitalizations.
The incident is the worst of its kind to have taken place in France, which has launched three separate investigations to determine whether the tragedy was caused by an error in the trial’s procedures or in the substance tested, according to an article posted online on January 17 by the U.K. Guardian newspaper.
The private laboratory Biotrial was testing a pain and mood disorder medication for the Portuguese pharmaceutical company Bial on humans for the first time, in a Phase I trial to test the drug’s safety. A total of 108 volunteers took part in the trial, 90 of whom received the drug at varying doses, while the rest were given placebos. Six men in the group that received the highest dose suffered serious side effect and were hospitalized, the article noted.
Dr. Pierre-Gilles Edan, head of the neurology department at the Rennes hospital, said that three of the men were suffering a “handicap that could be irreversible” and another also had neurological problems. The sixth volunteer had no symptoms but was being monitored, according to the Guardian report.
The 84 other volunteers exposed to the drug have been contacted by hospital staff. Ten of them came in to be examined and did not have the anomalies seen in the hospitalized patients.
Bial is cooperating with the investigation and claims it followed international best practice in developing the drug. According to a company statement, “Our principal concern at the moment is taking care of participants in the trial.”
For more details, see the following article posted by Nature.com.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
